Novavax final results show 96% efficacy in UK trial but plunge to about 50% in South African variant
Matching Pfizer and Moderna, Novavax unveiled final results Thursday afternoon from its Covid-19 vaccine trials in the UK and South Africa, showing its candidate proved to be 96% effective against mild, moderate and severe Covid-19 cases in the UK.
And while the vaccine posted just 50% efficacy against the South African variant, across both trials the shot demonstrated complete protection against severe Covid-19, including all hospitalizations and deaths, Novavax said. But with only five severe cases occurring in the placebo arms of each trial, some physicians are questioning whether that’s enough data to actually show complete protection.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.